newsfilter
← Latest News
GlobeNewswire·

Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity

IKT
  • Inhibikase Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $20.5 million ($0.10 per share) and cash, cash equivalents, and marketable securities totaling $193.3 million.
  • The Phase 3 IMPROVE-PAH study for IKT-001 has obtained regulatory approvals in 28 countries with 79 of 180 planned sites activated as of November 2026.
  • The global IMPROVE-PAH trial is a two-part adaptive study: Part A (approx. 140 patients) measures Pulmonary Vascular Resistance at Week 24, while Part B (approx. 346 patients) measures 6-minute walk distance at Week 24.
  • An interim safety readout for Part A of the IMPROVE-PAH study involving 50 patients is planned for the first half of 2027.
  • Scott M. Wasserman, MD, was appointed to the Board of Directors in October 2026, bringing over two decades of clinical development experience.
  • In July 2026, the Company raised $50 million by selling 25 million shares to RA Capital Management, with 18.03 million shares subsequently exchanged for pre-funded warrants.
  • The FDA granted Orphan Drug Designation for IKT-001 in July 2026, providing incentives including tax credits, fee exemptions, and seven years of market exclusivity.
  • Nonclinical studies are underway to evaluate IKT-001 in combination with sotatercept, with results expected starting in Q1 2027, and to assess potential benefits in Group 2 and Group 3 pulmonary hypertension.
  • Research and development expenses increased to $15.0 million for the quarter and $39.2 million for the nine months ended September 30, 2026, compared to prior year figures.
  • Selling, general, and administrative expenses were $7.2 million for the quarter and $22.3 million for the nine months ended September 30, 2026.
  • Upcoming investor engagements include the Jefferies Global Healthcare Conference (November 16–19, 2026) in London and the 9th Annual Evercore Healthcare Conference (November 30–December 2, 2026) in Coral Gables, Florida.
Company
Inhibikase Therapeutics
Keywords
Nasdaq:IKT, Inhibikase Therapeutics